Skip to content

Thymosin Beta-4

Also called TB4 (full-length)

Full-length actin-sequestering peptide (TB-500 is its active fragment).

  • TypePeptide
  • FormInjectable
  • Researched forHealing & Recovery

Where to get Thymosin Beta-4

Ion Peptide
Injectable
Code CAMERON

The only form sold. Research compound, not approved for human use.

Shop injectable at Ion Peptide

The short version

  • Why people research itSoft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
  • What the evidence isThe parent protein TB-500 is a fragment of, and it reached phase 2 in humans — RegeneRx ran trials in dry eye disease and in venous stasis and pressure ulcers.
  • What to watchA mole or lump that changes.

How Thymosin Beta-4 works

Full-length actin-sequestering peptide (TB-500 is its active fragment) — drives cell migration, angiogenesis, and tissue/cardiac repair.

This page is about the intact 43-residue protein, and the reason it needs its own page is that the fragment sold as TB-500 is missing the half of the molecule that does the anti-inflammatory work. Mature thymosin beta-4 is Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser, acetylated at the N-terminus.

The site map, which is the single most useful published fact about this protein. Its activities are assigned to distinct short sequences, not to the molecule as a whole Sosne 2010:

  • Injectable

On the goal map: Thymic function & adaptive immunity (Immune resilience)

Research on Thymosin Beta-44 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • The parent protein TB-500 is a fragment of, and it reached phase 2 in humans — RegeneRx ran trials in dry eye disease and in venous stasis and pressure ulcers. The dry-eye program reported improvement in signs and symptoms; the wound program showed acceleration of healing in some cohorts. Neither reached approval and development stalled on funding rather than on a safety finding.

Correlative data

  • Used interchangeably with TB-500 in practice, though they are not the same molecule — the full 43-amino-acid protein versus the active fragment. Reported experience is indistinguishable, which is unsurprising given the fragment carries the actin-binding domain that does the work.

How the mechanism reads

  • An actin-sequestering protein present in most cells and elevated at wound sites. It promotes cell migration, angiogenesis and downregulation of inflammatory cytokines — a broader mechanism than the fragment alone.

    Mechanistic
  • The same pro-migratory, pro-angiogenic activity carries the same unanswerable long-term question as every repair peptide here.

    Mechanistic

Sources

  • Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal 2010 · PMID 20179146
  • Wang W, et al. The Role of Tbeta4-POP-Ac-SDKP Axis in Organ Fibrosis. International Journal of Molecular Sciences 2022 · PMID 36362069
  • Zoubek RE, Hannappel E. Influence of the N terminus and the actin-binding motif of thymosin beta4 on its interaction with G-actin. Annals of the New York Academy of Sciences 2007 · PMID 17495251
  • Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration 2003 · PMID 12581423
  • Sosne G, et al. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 2015 · PMID 25826322
  • Sosne G, et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clinical Ophthalmology 2015 · PMID 26056426
  • Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences 2007 · PMID 17495250
  • Wang X, et al. Journal of Cellular and Molecular Medicine 2021 · PMID 34346165

Thymosin Beta-4 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Cancer history or an undiagnosed mass: actin-driven migration and angiogenesis help tumor growth.
  • Proliferative eye disease: more angiogenic signaling worsens abnormal vessels.
  • Pregnancy: angiogenesis and cell migration signals in placental tissue are untested.
  • Very recent heart attack or stroke: effects on healing vessels are not human-tested.

What’s expected

  • Possible sense of recovery, with its actin-sequestering action aiding cell migration and repair.
  • Light-headedness or flushing after use.
  • No firm human efficacy data.

Watch for

  • A mole or lump that changes.
  • Vision change or floaters while using Thymosin Beta-4.
  • Chest pain or palpitations.
  • Spreading redness.

Labs that tell you it’s working

  • hs-CRP (C-Reactive Protein, High Sensitivity)
  • Complete Blood Count (CBC) w/ Differential
  • Fibrinogen Activity
  • Comprehensive Metabolic Panel (CMP)

Thymosin beta-4 is the full-length actin-sequestering protein behind TB-500, with cardiac repair data in animals; evidence is animal and anecdotal. PMID 10469335 PMID 26056426

Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON

Thymosin Beta-4 FAQ4 common questions

Is Thymosin Beta-4 approved for human use?
No. Thymosin Beta-4 is a research compound.
What is Thymosin Beta-4 researched for?
Soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Which labs show whether it's doing anything?
hs-CRP; Complete Blood Count; Fibrinogen Activity; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Thymosin Beta-4: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Thymosin Beta-4 is. Skool covers how it is run.

Free on this page

What Thymosin Beta-4 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Thymosin Beta-4 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool